Israel - English - Ministry of Health

rekah pharmaceutical industry ltd, israel - dexamethasone - tablets - dexamethasone 2 mg - dexamethasone - dexamethasone - indicated in a wide variety of disorders amenable to glucocorticoid therapy, as well as an adjunct in the control of cerebral oedema.

Israel - English - Ministry of Health

rekah pharmaceutical industry ltd, israel - dexamethasone - tablets - dexamethasone 0.5 mg - dexamethasone - dexamethasone - indicated in a wide variety of disorders amenable to glucocorticoid therapy, as well as an adjunct in the control of cerebral oedema.

Israel - English - Ministry of Health

a.l. medi-market ltd. - dexamethasone phosphate (as sodium) - solution for injection / infusion - dexamethasone phosphate (as sodium) 4 mg / 1 ml - dexamethasone - dexamethasone rompharm is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematological: acquired )autoimmune( haemolytic anaemia, idiopathic thrombocytopenic purpura, pure red cell aplasia• nephrotic syndrome of the idioplathic type or that due to lupus erythematosus• cerebral edema caused by brain tumor, neurosurgery, brain abscess, bacterial meningitis• collagen diseases: active rheumatoid arthritis with severe progressive course, fast destructive remitting forms and / or extra-articular manifestations, juvenile idiopathic arthritis with severe systemic-onset form (still's disease) or locally with no control, rheumatic fever with carditis, dermatomyositis, polymyositis, sle, temporal arteritis.• infectious diseases: bacterial meningitis – adjunct to antibiotics in suspected pneumococcal meningitis and tb meningitis. severe infectious diseases with toxic states (eg tuberculosis, typhoid, brucellosis;. only with simultaneous anti-infective therapy)• fetal lung maturation• chemotherapy – associated nausea and vomiting• multiple myeloma – part of chemotherapy protocols (eg vad)• prevention and treatment of acute mountain sickness/hace

Israel - English - Ministry of Health

pharmalogic ltd - dexamethasone phosphate (as sodium) - solution for injection / infusion - dexamethasone phosphate (as sodium) 4 mg / 1 ml - dexamethasone - dexamethasone panpharma is indicated in the treatment ofendocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs. ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers. inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis. dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome) haematological: acquired )autoimmune( haemolytic anaemia, idiopathic thrombocytopenic purpura in adult, pure red cell aplasia nephrotic syndrome of the idiopathic type or that due to lupus erythematosus cerebral oedema caused by brain tumor, neurosurgery, brain abscess, bacterial meningitis collagen diseases: active rheumatoid arthritis with severe progressive course, fast destructive remitting forms and / or extra-articular manifestations, juvenile idiopathic arthritis with severe systemic-onset form (still's disease) or locally with no control, rheumatic fever with carditis, dermatomyositis, polymyositis, sle, temporal arteritis. infectious diseases: bacterial meningitis – adjunct to antibiotics in suspected pneumococcal meningitis and tb meningitis. severe infectious diseases with toxic states (eg tuberculosis, typhoid, brucellosis;. only with simultaneous anti-infective therapy) fetal lung maturation chemotherapy – associated nausea and vomiting multiple myeloma – part of chemotherapy protocols (eg vad) prevention and treatment of acute mountain sickness/hace

Malta - English - Medicines Authority

syri pharma limited floor 0 1 wml, 1 windmill lane dublin 2, d02 f206, ireland - dexamethasone - oral solution - dexamethasone 2 mg - corticosteroids for systemic use

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml - solution for injection - 4 mg/ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml excipient: disodium edetate nitrogen propylene glycol sodium hydroxide water for injection - dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid. when so supplemented, dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy; · relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available; · primary and secondary adrenocortical insufficiency.

Ireland - English - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - dexamethasone sodium phosphate - oral solution - 10 mg/5ml - glucocorticoids; dexamethasone

Malta - English - Medicines Authority

rosemont pharmaceuticals limited rosemont house, yorkdale industrial park, braithwaite street, leeds ls11 9xe, united kingdom - dexamethasone - oral solution - dexamethasone 10 mg/5ml - corticosteroids for systemic use

United States - English - NLM (National Library of Medicine)

mwi/vetone - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 3 mg in 1 ml - indications and usage: dexamethasone-sp (dexamethasone sodium phosphate) is indicated as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses. contraindications: do not use in viral infections. except when used for emergency therapy, dexamethasone sodium phosphate is contraindicated in animals with tuberculosis and chronic nephritis. existence of congestive heart failure, osteoporosis and diabetes are relative contraindications. in the presence of infection appropriate antibacterial agents should also be administered and should be continued for at least 3 days after discontinuance of the hormone and disappearance of all signs of infection.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - dexamethasone - oral tablet - 2mg